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IMPORTANCE Efficacy of cannabidiol has been demonstrated in seizures associated with
Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in
conditions with primarily focal seizures, such as tuberous sclerosis complex (TSC).
OBJECTIVE To evaluate efficacy and safety of 25-mg/kg/day and 50-mg/kg/day cannabidiol
dosages vs placebo against seizures associated with TSC.
DESIGN, SETTING, AND PARTICIPANTS This double-blind, placebo-controlled randomized
clinical trial (GWPCARE6) enrolled patients between April 6, 2016, and October 4, 2018;
follow-up was completed on February 15, 2019. The trial was conducted at 46 sites in
Australia, Poland, Spain, the Netherlands, United Kingdom, and United States. Eligible
patients (aged 1-65 years) were those with a clinical diagnosis of TSC and medication-
resistant epilepsy who had had at least 8 TSC-associated seizures during the 4-week baseline
period, with at least 1 seizure occurring in at least 3 of the 4 weeks, and were currently taking
at least 1 antiepileptic medication.
INTERVENTIONS Patients received oral cannabidiol at 25 mg/kg/day (CBD25) or 50
mg/kg/day (CBD50) or a matched placebo for 16 weeks.
MAIN OUTCOMES AND MEASURES The prespecified primary outcome was the change from
baseline in number of TSC-associated seizures for cannabidiol vs placebo during the
treatment period.
RESULTS Of 255 patients screened for eligibility, 31 were excluded and 224 were randomized.
Of the 224 included patients (median [range] age, 11.4 [1.1-56.8] years; 93 female patients
[41.5%]), 75 were randomized to CBD25, 73 to CBD50, and 76 to placebo, with 201
completing treatment. The percentage reduction from baseline in the type of seizures
considered the primary end point was 48.6% (95% CI, 40.4%-55.8%) for the CBD25 group,
47.5% (95% CI, 39.0%-54.8%) for the CBD50 group, and 26.5% (95% CI, 14.9%-36.5%) for
the placebo group; the percentage reduction from placebo was 30.1% (95% CI, 13.9%-43.3%;
P < .001) for the CBD25 group and 28.5% (95% CI, 11.9%-42.0%; nominal P = .002) for the
CBD50 group. The most common adverse events were diarrhea (placebo group, 19 [25%];
CBD25 group, 23 [31%]; CBD50 group, 41 [56%]) and somnolence (placebo group, 7 [9%];
CBD25 group, 10 [13%]; CBD50 group, 19 [26%]), which occurred more frequently with
cannabidiol than placebo. Eight patients in CBD25 group, 10 in CBD50 group, and 2 in the
placebo group discontinued treatment because of adverse events. Twenty-eight patients
taking cannabidiol (18.9%) had elevated liver transaminase levels vs none taking placebo.
CONCLUSIONS AND RELEVANCE Cannabidiol significantly reduced TSC-associated seizures
compared with placebo. The 25-mg/kg/day dosage had a better safety profile than the
50-mg/kg/day dosage.
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T uberous sclerosis complex (TSC) is a disorder caused byautosomal-dominant sequence variations in the TSC1and/or TSC2 genes, resulting in upregulation of the
mechanistic target of rapamycin (mTOR) pathway with sub-
sequent excessive cell growth and proliferation.1-4 Tuberous
sclerosis complex is characterized by the occurrence of be-
nign hamartomas in multiple organ systems, most fre-
quently in brain, skin, kidneys, lungs, heart, and eyes.1,5 Inci-
dence of TSC is estimated at 1 in 6000 live births, affecting 1
to 2 million individuals worldwide.6,7
Epilepsy is the most common neurologic manifestation of
TSC, affecting approximately 85% of patients, with onset often
during infancy.8-12 Patients experience focal seizures and infan-
tile spasms as infants and a variety of other seizures during their
lifetime.10,13 Despite several treatment options for TSC-
associated seizures—including antiepileptic drugs such as viga-
batrin, the mTOR inhibitor everolimus, surgical procedures, and
dietary therapy14—more than 60% of patients have treatment-
resistant epilepsy,13 which is associated with neurodevelopmen-
tal disorders, including autism and intellectual disability.11,15
Cannabidiol is approved as Epidiolex in the US for treat-
ment of seizures associated with Lennox-Gastaut syndrome,
Dravet syndrome, or TSC in patients 1 year and older, and as
Epidyolex in the European Union in conjunction with cloba-
zam for Lennox-Gastaut syndrome and Dravet syndrome in pa-
tients 2 years and older.16,17 Efficacy of cannabidiol was first
demonstrated against Dravet syndrome–associated and Lennox-
Gastaut syndrome–associated seizures.18-21 On the basis of data
from patients with TSC in an expanded-access program,22 we
conducted a placebo-controlled randomized clinical trial to
assess efficacy and safety of add-on cannabidiol for the
treatment of TSC-associated seizures (primarily focal seizures)
in children and adults.
Methods
Study Design and Participants
This was a phase 3, international, double-blind, parallel-
group randomized clinical trial of add-on cannabidiol vs pla-
cebo in patients with TSC and drug-resistant epilepsy. The trial
consisted of a 4-week baseline period, a 16-week treatment pe-
riod (4 weeks for dose escalation [titration period] followed by
12 weeks of stable dosing [maintenance period]), a taper pe-
riod of up to 10 days, and a 4-week safety follow-up (eFigure 1
in Supplement 1). The protocol was approved by an institu-
tional review board or ethics committee at each participating
site and conducted in accordance with the principles of the Dec-
laration of Helsinki and the International Conference on Har-
monisation Tripartite Guideline on Good Clinical Practice. All
patients or caregivers provided written informed consent, and
patients developmentally mature enough to understand the
trial provided assent. All authors vouch for the accuracy of the
reported results and adherence to the protocol. The manu-
script was written by all authors, 3 of whom are GW Pharma-
ceuticals employees (F.S., D.C., and V.K.).
Eligible patients (aged 1-65 years) with a definite clinical
diagnosis of TSC1 and medication-resistant epilepsy had at least
8 TSC-associated seizures during the 4-week baseline period
with at least 1 seizure occurring in at least 3 of the 4 weeks and
were taking at least 1 antiepileptic medication. Key exclusion
criteria were a history of nonepileptic seizures, clinically sig-
nificant illness other than epilepsy, epilepsy surgery in the 6
months before screening, felbamate use for less than 1 year be-
fore screening, and use of oral mTOR inhibitors. Details of eli-
gibility criteria are provided in eTable 1 in Supplement 1.
Randomization, Concealment, and Masking
After screening and the baseline period, eligible patients were
randomized equally to receive a pharmaceutical formulation of
highly purified cannabidiol derived from Cannabis sativa L. (100
mg/mL oral solution; Epidiolex in the US; Epidyolex in the Eu-
ropean Union [GW Research Ltd]) at 25 mg/kg of body weight
per day (CBD25 group), 50 mg/kg/day (CBD50 group), or pla-
cebo. Patients in the placebo group were subdivided to receive
a placebo matching either the 25-mg/kg/day or 50-mg/kg/day
dosage of CBD. The placebo groups were pooled for reporting
efficacy and safety results. The randomization schedule was cre-
ated by an independent statistician and stratified by age group
(1-6, 7-11, 12-17, and 18-65 years). Cannabidiol solutions and pla-
cebo solutions (excipients alone) were provided in identical
100-mL amber glass bottles.
Procedures
Study drugs were administered twice daily in equally divided
doses with a faster titration schedule than prior studies: dos-
ages started at 5 mg/kg/day and reached 25 mg/kg/day on day
9 and 50 mg/kg/day on day 29 (eFigure 2 in Supplement 1). The
number and type of seizures and status epilepticus episodes
were reported daily using an interactive voice-response sys-
tem, and adverse events and medications were recorded using
a paper-based diary. Details of the trial procedures are avail-
able in the protocol (Supplement 2). Patients who completed
treatment were eligible to enter an open-label extension phase
(NCT02544750). Patients who withdrew from the study or did
not enter the open-label extension were seen at 4 weeks after
the last dose. An independent safety monitoring committee
approved the higher dosages used in this trial and monitored
Key Points
Question Is add-on cannabidiol superior to placebo in reducing
the number of seizures associated with tuberous sclerosis
complex?
Findings In this randomized clinical trial, 224 patients with
tuberous sclerosis complex were treated with cannabidiol (25 or
50 mg/kg/day) or matched placebo for 16 weeks. The percentage
reduction in the type of seizures regarded as the primary end point
was 27% for placebo, 49% for 25 mg/kg/day of cannabidiol, and
48% for 50 mg/kg/day of cannabidiol; a dosage of 25 mg/kg/day
led to fewer adverse events than the 50-mg/kg/day dosage.
Meaning In this study, both cannabidiol dosages were equally
efficacious in reducing tuberous sclerosis complex–associated
seizures compared with placebo, but the smaller dosage led to
fewer adverse events.
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patient safety. An adjudication committee evaluated any
potential signs of abuse.
Outcome Measures
The primary end point was the change from baseline in the
number of TSC-associated seizures in patients taking add-on
cannabidiol vs placebo during the 16-week treatment period.
The primary end point, TSC-associated seizures, included
countable focal motor seizures without impairment of aware-
ness, focal seizures with impairment of awareness, focal sei-
zures evolving to bilateral motor seizures, and generalized
seizures (tonic-clonic, tonic, clonic, or atonic); this excluded
absence, myoclonic, and focal sensory seizures and infantile/
epileptic spasms. A mean of 94% of patients’ baseline
seizures were classified as TSC-associated seizures. This func-
tional definition and classification of the primary–end-point,
TSC-associated seizures was reviewed and approved by the US
Food and Drug Administration, the European Medicines
Agency, and the Epilepsy Study Consortium independent
committee of experts.
Key secondary outcomes included the proportion of pa-
tients who had at least a 50% reduction from baseline in primary–
end-point seizures; the participants’ or caregivers’ global im-
pressions of change from baseline in overall condition, as
assessed on a 7-point Likert scale that included 3 categories for
improvement (ie, slightly improved, much improved, and very
much improved), 3 for worsening (slightly worse, much worse,
and very much worse), and an option to indicate no change; and
the change from baseline in total seizures (ie, sum of all indi-
vidual seizure types). Other secondary outcomes are described
in the eMethods in Supplement 1. We also conducted a prespeci-
fied analysis to explore the effect of concomitant clobazam on
the change in primary–end-point seizures.
Statistical Analysis
We assumed a reduction from baseline in seizures of 15% for
placebo and 50% for cannabidiol with a common SD of 60%,
leading to a sample size of 70 patients per treatment group with
90% power to detect a difference in response distributions. The
primary analyses for all outcomes used the intention-to-treat
data set, which included all randomized patients. The per-
protocol data set, including patients who completed the study
without major protocol deviations, was used in sensitivity
analyses for the primary and key secondary outcomes. All sta-
tistical tests were 2-sided with a 5% significance level.
Negative binomial regression on the sum of the seizure
counts during the treatment period was used for the primary
outcome analysis and is described in the eMethods in Supple-
ment 1, along with a description of statistical analyses used for
all secondary outcomes. Type I error was controlled by a hi-
erarchical gatekeeping procedure (eTable 2 in Supplement 1),
wherein each successive end point was tested for inferential
statistical significance only if the preceding comparison was
statistically significant; otherwise, resultant P values were des-
ignated as nominal and used descriptively. All statistical analy-
ses were done using SAS version 9.3 or higher (SAS Institute),
and the threshold of significance was P < .05.
Results
Patients
Between April 6, 2016, and October 4, 2018, 255 patients were
assessed for eligibility at 46 sites; 224 patients (median [range]
age, 11.4 [1.1-56.8] years; 93 female patients [41.5%]) under-
went randomization (US, 112; Poland, 61; Australia, 24; Spain,
11; the Netherlands, 9; UK, 7) to the CBD25 group (n = 75), the
Figure 1. Screening, Randomization, and Treatment Period
255 Patients assessed for eligibility
76 Assigned to placebo group
38 Received placebo at volumes
equivalent to 25 mg/kg/d 
cannabidiol dosage
38 Received placebo at volumes
equivalent to 50 mg/kg/d
cannabidiol dosage
75 Assigned to 25 mg/kg/d
cannabidiol group
65 Receiving target dosage
at the end of treatment
73 Assigned to 50 mg/kg/d
cannabidiol group
39 Receiving target dosage
at the end of treatment
224 Patients randomized
75 Completed the treatment period
75 Entered the open-label
extension trial
1 Discontinued treatment
because they were
withdrawn by caregiver
65 Completed the treatment period
64 Entered the open-label
extension trial
10 Discontinued treatment
8 Had an adverse eventb
1 Withdrawn by caregiver
1 For other reasonsc
12 Discontinued treatment
8 Had an adverse eventb
2 Met withdrawal criteriad
1 Withdrawn by
investigator
1 Withdrawn by caregiver
61 Completed the treatment period
60 Entered the open-label
extension trial
31 Excludeda
17 Did not meet eligibility criteria
5 Withdrew or were withdrawn by caregiver
2 Withdrawn by investigator
8 For other reasons
a Patients may have more than 1
reason for exclusion.
b Patients had adverse event as the
primary reason for discontinuation.
c One patient in the 25–mg/kg/d
cannabidiol group discontinued
treatment because of difficulty
taking the study medication,
problems with eating and drinking,
occurrence of constipation, and
increase in seizures.
d Two patients in the 50–mg/kg/d
cannabidiol group met the
withdrawal criteria via elevations in
alanine aminotransferase or
aspartate aminotransferase levels.
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CBD50 group (n = 73), and the placebo group (n = 76) (Figure 1).
Not all patients reached or remained at their assigned dosage
(eTable 3 in Supplement 1); 87% (65 of 75 patients) in the CBD25
group and 53% (39 of 73 patients) in the CBD50 group were re-
ceiving their target dosage at treatment end. The mean of each
patient’s modal dosage was 24 mg/kg/day in the CBD25 group
and 36 mg/kg/day in the CBD50 group.
Overall, the following 23 patients (10.3%) discontinued
treatment and were excluded from the per-protocol analysis
set: 12 (16%) in the CBD50 group, 10 (13%) in the CBD25 group,
and 1 (1%) in the placebo group. Sixteen of 22 patients taking
cannabidiol had an adverse event as the primary reason for dis-
continuation. Overall, 201 patients completed treatment; of
those, 199 (99%) entered the open-label extension trial.
Baseline characteristics were similar between the treat-
ment groups (Table 1). Patients had previously discontinued
a median (range) of 4 (0-15) antiepileptic drugs and were
concurrently taking a median (range) of 3 (0-5) antiepileptic
drugs. The median (interquartile range [IQR]) number of pri-
mary–end-point seizures was 56.9 (28.5-107.4) in the 4-week
baseline period.
Primary Outcome
A reduction from baseline in primary–end-point seizures of
48.6% (95% CI, 40.4%-55.8%) was observed for the CBD25
group, 47.5% (95% CI, 39.0%-54.8%) for the CBD50 group, and
26.5% (95% CI, 14.9%-36.5%) for the placebo group during the
treatment period (Figure 2A). The percentage reduction from
Table 1. Demographic and Clinical Characteristics of Patients at Baseline
Characteristic
No. (%)
Treatment group
Placebo (n = 76) CBD25 (n = 75) CBD50 (n = 73)
Age, median (range), y 10.9 (1.2-55.8) 11.6 (1.1-56.8) 10.2 (1.8-34.9)
Age, y
1-6 22 (29) 21 (28) 21 (29)
7-11 18 (24) 18 (24) 18 (25)
12-17 16 (21) 16 (21) 16 (22)
18-65 20 (26) 20 (27) 18 (25)
Male 45 (59) 43 (57) 43 (59)
Median No. of prior antiepileptic drugs
(range)
4 (0-15) 4 (0-13) 4 (0-13)
No. of concomitant antiepileptic drugs
Median (range) 3 (1-5) 3 (0-4) 3 (1-5)
1 8 (11) 9 (12) 7 (10)
2 27 (36) 20 (27) 24 (33)
≥3 41 (54) 45 (60) 42 (58)
Median No. of prior and current antiepileptic
drugs (range)
7 (2-18) 7 (1-15) 7 (1-15)
Concomitant antiepileptic drugs
Valproate 35 (46) 29 (39) 36 (49)
Vigabatrin 17 (22) 28 (37) 29 (40)
Levetiracetam 24 (32) 19 (25) 22 (30)
Clobazam 25 (33) 17 (23) 19 (26)
Prior antiepileptic drugs not currently taken
Valproate 23 (30) 28 (37) 25 (34)
Vigabatrin 42 (55) 26 (35) 29 (40)
Levetiracetam 36 (47) 39 (52) 33 (45)
Clobazam 22 (29) 24 (32) 16 (22)
Everolimus 7 (9) 7 (9) 7 (10)
Median No. of seizures during the 28-d
baseline period (IQR)
Primary–end-point seizuresa 54.1 (26.4-102.0) 56.0 (21.2-101.0) 61.0 (36.0-117.0)
Total seizuresb 56.5 (27.5-138.1) 56.0 (22.6-101.0) 70.0 (38.0-130.0)
Seizure subtypes during the 28-d baseline
period
Focal seizures without impaired awareness 33 (43) 29 (39) 39 (53)
Focal seizures with impaired awareness 50 (66) 46 (61) 54 (74)
Focal to bilateral motor seizures 24 (32) 17 (23) 24 (33)
Tonic-clonic 14 (18) 22 (29) 16 (22)
Tonic 15 (20) 27 (36) 23 (32)
Clonic 2 (3) 3 (4) 3 (4)
Atonic 13 (17) 10 (13) 5 (7)
Otherc 15 (20) 12 (16) 24 (33)
Abbreviations: CBD25, cannabidiol
25 mg/kg/day; CBD50, cannabidiol
50 mg/kg/day; IQR, interquartile
range; TSC, tuberous sclerosis
complex.
a The TSC-associated seizures for this
trial were defined as countable focal
motor seizures without impairment
of awareness, focal seizures with
impairment of awareness, focal
seizures evolving to bilateral motor
seizures, and generalized seizures
(tonic-clonic, tonic, clonic, or
atonic).
b Total seizures include all seizure
types combined, including focal
sensory seizures and epileptic
spasms.
c Other seizures include absence,
myoclonic, and focal sensory
seizures and infantile or epileptic
spasms.
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placebo was 30.1% (95% CI, 13.9%-43.3%; P < .001) for the
CBD25 group and 28.5% (95% CI, 11.9%-42.0%; nominal
P = .002) for the CBD50 group. During the maintenance pe-
riod, patients had a 36.9% reduction in primary–end-point
seizures from placebo for both the CBD25 and the CBD50
groups (eFigure 3 in Supplement 1). This treatment effect on
the primary end point was evident regardless of concomitant
clobazam use (Figure 3). Results of the sensitivity analyses were
consistent with the primary outcome (eFigure 4 in Supple-
ment 1). In particular, other statistical methods used in sen-
sitivity analyses of the primary outcome yielded similar
results: median (IQR) percentage reductions of 43.4% (13.6%-
67.8%; P = .004) for the CBD25 group and 36.6% (5.5%-
67.0%; P = .009) for the CBD50 group vs 20.1% (3.1%-47.1%)
with placebo using the Wilcoxon rank-sum test; geometric
mean percentage reductions of 48.3% (95% CI, 32.9%-60.1%;
P = .002) for CBD25 and 49.3% (95% CI, 34.4%-60.8%;
P = .002) for CBD50 vs 23.9% (95% CI, 1.3%-41.3%) for
placebo, using log-transformed analysis of covariance; and
least square mean percentage reductions of 35.6% (95% CI,
26.1%-45.0%; P = .03) for CBD25 and 35.2% (95% CI, 25.6%-
44.7%; P = .03) for CBD50 vs 20.4% (95% CI, 11.1%-29.8%) for
placebo using analysis of covariance. A reduction in primary–
end-point seizures was observed during the titration period
and maintained throughout the treatment period (eFigure 5
in Supplement 1). Reductions in primary–end-point seizures
were 47.9% (95% CI, 39.0%-55.6%) in the CBD25 group and
48.9% (95% CI, 36.7%-58.8%) in the CBD50 group vs 27.0%
(95% CI, 15.9%-36.6%) in the placebo group when patients who
withdrew or patients whose modal dosage was less than their
randomized dosage were excluded from the analysis.
Key Secondary Outcomes
Primary–end-pointseizureswerereducedatleast50%frombase-
line during the treatment period in 27 of 75 patients (36%) in the
CBD25 group, 29 of 73 patients (40%) in the CBD50 group, and
17 of 76 patients (22%) in the placebo group (Figure 2B). Similar
results were observed during the maintenance period (eFig-
ure 3B in Supplement 1). Twenty-five patients (16.9%) taking can-
nabidiol had at least a 75% reduction in seizures, vs none tak-
ing placebo (Figure 2B). One patient in the CBD25 group was
seizure free during the full treatment period; 4 patients in the
CBD25 group, 2 in the CBD50 group, and none in the placebo
group were seizure free during the maintenance period.
At treatment end, 48 of 70 patients (69%) in the CBD25
group, 43 of 69 patients (62%) in the CBD50 group, and 30 of
76 patients (39%) in the placebo group reported improve-
ment from baseline in overall condition, according to the
participants’ or caregivers’ global impression of change (eFig-
ure 6 in Supplement 1). The odds ratios were 2.25 (95% CI, 1.24-
4.07; nominal P = .007) for CBD25 vs placebo and 1.77 (95%
CI, 0.98-3.20; nominal P = .06) for CBD50 vs placebo.
The percentage reduction from baseline in total seizures
was 48.1% (95% CI, 39.8%-55.3%) for the CBD25 group, 47.6%
(95% CI, 39.3%-54.8%) for the CBD50 group, and 26.9% (95%
CI, 15.4%-36.8%) for the placebo group during the treatment
period (Figure 2A). During the maintenance period, a 35.6%
(95% CI, 17.1%-50.0%) reduction in total seizures compared
Figure 2. Seizure Outcomes During the Treatment Period
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A, Reduction from baseline in the frequency of primary–end-point and total
seizures. B, Proportion of patients with a 50% or more and 75% or more
reduction from baseline in primary–end-point seizures. Negative binomial
regression was used to compare seizure frequency between cannabidiol groups
with placebo. The treatment period (16 weeks) constituted the titration and
maintenance phases. The estimated ratio of least squares means for the
treatment period to baseline period was used to evaluate the reduction in
seizure frequency. The P values for the testing of the null hypothesis that the
estimated ratio of each cannabidiol group to placebo was 1 are presented. The
primary–end-point seizures are all countable focal motor seizures without
impairment of awareness, focal seizures with impairment of awareness, focal
seizures evolving to bilateral motor seizures, and generalized seizures
(tonic-clonic, tonic, clonic, or atonic). Total seizures include all types combined,
including focal sensory seizures and epileptic spasms. The odds ratios are
presented for the comparisons in a 50% responder rate between the placebo
group and the groups receiving 25–mg/kg/d and 50–mg/kg/d of cannabidiol.
The P values were calculated from a Cochran–Mantel-Haenszel test stratified by
age group (1-6, 7-11, 12-17, and 18-65 years). The percentage reduction in
primary–end-point seizures from placebo was 30.1% (95% CI, 13.9%-43.3%;
P < .001) in the cannabidiol 25 mg/kg/day (CBD25) group and 28.5% (95% CI,
11.9%-42.0%; nominal P = .002) in the cannabidiol 50 mg/kg/day (CBD50)
group. The percentage reduction in total seizures from placebo was 29.1% (95%
CI, 12.7% to 42.4%; nominal P = .001) in the CBD25 group and 28.4% (95% CI,
11.8% to 41.8%; nominal P = .002) in the CBD50 group. Note: the P values
displayed in the Figure are nominal values.
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with the level in the placebo group was observed for the CBD25
group; it was 37.0% (95% CI, 18.6%-51.2%) for the CBD50 group
(eFigure 3 in Supplement 1).
Other Outcomes
During the 4-week baseline, patients had a mean (SD) of 7 (7)
seizure-free days. During the 12-week maintenance period, pa-
tients in cannabidiol groups gained a mean of 10 (95% CI, 3-17)
or 8 (95% CI, 1-15) additional seizure-free days over placebo in
the CBD25 and CBD50 groups, respectively. Results of all other
secondary outcomes analyses are presented in eTable 4 in
Supplement 1.
Adverse Events
Adverse events were reported by 70 patients (93%) in the CBD25
group, 73 patients (100%) in the CBD50 group, and 72 patients
(95%) in the placebo group; 88% of the adverse events were mild
or moderate. The most common adverse events in the canna-
bidiol groups were diarrhea (placebo group, 19 [25%]; CBD25
group, 23 [31%]; CBD50 group, 41 [56%]), somnolence (pla-
cebo group, 7 [9%]; CBD25 group, 10 [13%]; CBD50 group, 19
[26%]), decreased appetite (placebo group, 9 [12%]; CBD25
group, 15 [20%]; CBD50 group, 17 [23%]), and liver transami-
nase level elevations (alanine aminotransferase level in-
creased: placebo group: 0; CBD25 group, 9 [12%]; CBD50 group,
16 [22%]; aspartate aminotransferase level increased: placebo
group, 0; CBD25 group, 8 [11%]; CBD50 group, 14 [19%])
(Table 2). In patients taking CBD with clobazam vs without clo-
bazam, somnolence (placebo: 3 of 25 [12%] vs 4 of 51 [8%];
CBD25, 5 of 17 [29%] vs 5 of 58 [9%]; CBD50, 10 of 19 [53%] vs 9
of 54 [17%]), rash (placebo: 2 of 25 [8%] vs 0 of 51; CBD25, 2 of
17 [12%] vs 2 of 58 [3%]; CBD50, 1 of 19 [5%] vs 6 of 54 [11%]),
and pneumonia (placebo, 0 of 25 vs 1 of 51 [2%]; CBD25, 2 of 17
[12%] vs 0 of 58; CBD50, 1 of 19 [5%] vs 1 of 54 [2%]) generally
occurred more frequently (eTable 5 in Supplement 1).
An adverse event was listed as one of the reasons for
treatment discontinuation in 20 patients (CBD25, 8 [11%];
CBD50, 10 [14%]; placebo, 2 [3%]); most common adverse
events leading to discontinuation were rash (CBD25 group, 2
patients [3%]; CBD50 group, 2 patients [3%]), alanine amino-
transferase level elevations, somnolence, and urticaria
(2 patients [3%] each in the CBD50 group). Nine patients (12%)
in the CBD25 group, 21 (29%) in the CBD50 group, and 4 (5%)
in the placebo group had permanent dosage reductions
because of an adverse event, most commonly diarrhea (pla-
cebo group, 1 [1%]; CBD25 group, 2 [3%]; CBD50 group, 7
[10%]) (eTable 6 in Supplement 1).
Serious adverse events were reported in 28 patients
(CBD25, 16 [21%]; CBD50, 10 [14%]; placebo, 2 [3%]); liver
enzyme level elevations were the most frequent serious
adverse events (eTable 7 in Supplement 1). No deaths were
reported.
Serum aminotransferase level elevations greater than 3
times the upper limit of the normal range occurred in 28 of 148
patients (18.9%) taking cannabidiol (CBD25, 9 of 75 [12%];
CBD50, 19 of 73 [26%]) and no patient taking a placebo; 22 of
28 affected patients (79%) were taking concomitant valpro-
ate (eTable 8 in Supplement 1). Most elevations occurred within
30 days of starting treatment and resolved either spontane-
ously, following treatment discontinuation, or after canna-
bidiol or antiepileptic drug dosage reduction (eTable 9 in
Supplement 1). No patient met the Hy’s Law criteria for
drug-induced liver injury. Additional safety, tolerability, and
laboratory parameters are included in the eResults in the
Supplement 1.
Discussion
This is the first randomized clinical trial to assess add-on can-
nabidiol in a disorder with primarily focal seizures, and the ef-
ficacy results are consistent with those from the 4 prior phase
3 trials of cannabidiol in the treatment of Lennox-Gastaut and
Dravet syndromes.18,20,21,23 Our trial included patients younger
than 2 years and used a much higher dosage of cannabidiol,
with an accelerated titration than previously tested. Patients
in this study had frequent and highly treatment-resistant sei-
zures; cannabidiol was their eighth attempted medication on
average. Nonetheless, cannabidiol led to meaningful reduc-
tions in seizures vs placebo observed as early as the titration
period and maintained throughout the study. Importantly, pa-
tients and caregivers perceived meaningful improvement in
overall condition, evident by participants’ and caregivers’
global impressions of change scores and enrollment in the
open-label extension phase.
Figure 3. Change From Baseline in Frequency of Primary–End-Point
Seizures During the Treatment Period in Patients Taking Cannabidiol
Without Clobazam and With Clobazam
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Negative binomial regression was used to compare seizure frequency between
the cannabidiol groups with the placebo group. The treatment period
(16 weeks) constituted the titration and maintenance phases. The estimated
ratio of least squares means for treatment period to baseline period was used to
evaluate the reduction in seizure frequency. The primary–end-point seizures are
all countable focal motor seizures without impairment of awareness, focal
seizures with impairment of awareness, focal seizures evolving to bilateral
motor seizures, and generalized seizures (tonic-clonic, tonic, clonic, or atonic).
The percentage reduction from placebo was 24.7% (95% CI, 3.7%-41.1%)
between placebo and cannabidiol 25 mg/kg/day (CBD25) groups and 22.0%
(95% CI, −0.1% to 39.1%) between the placebo and cannabidiol 50 mg/kg/day
(CBD50) groups among patients not taking clobazam and 46.6% (95% CI,
20.0%-64.4%) between the placebo and CBD25 groups and 46.6% (95% CI,
21.1%-63.9%) between the placebo and CBD50 groups among patients taking
clobazam.
Research Original Investigation Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex
E6 JAMA Neurology Published online December 21, 2020 (Reprinted) jamaneurology.com
Downloaded From: https://jamanetwork.com/ on 01/07/2021
Given the bidirectional drug-drug interaction between
cannabidiol and clobazam, in which exposure of the active
metabolite of each agent is increased,24,25 it is important to un-
derstand the clobazam-independent efficacy of cannabidiol.
This trial supports cannabidiol’s independent efficacy,
because most patients (73%) were not taking clobazam, and
cannabidiol was significantly more efficacious than placebo.
Furthermore, although subgroup analyses from individual
studies should be interpreted with caution, the treatment ef-
fect remained evident in the subgroup without clobazam. Can-
nabidiol administration has been shown to increase levels of
mTOR inhibitors everolimus and sirolimus26 and calcineurin
Table 2. Common Adverse Events Among Patients in the Safety Analysis Seta
Adverse event
Treatment group, No. (%)
Placebo (n = 76) CBD25 (n = 75) CBD50 (n = 73)
Diarrhea 19 (25) 23 (31) 41 (56)
Mild 16 (21) 20 (27) 35 (48)
Moderate 3 (4) 3 (4) 5 (7)
Severe 0 0 1 (1)
Somnolence 7 (9) 10 (13) 19 (26)
Mild 6 (8) 10 (13) 12 (16)
Moderate 1 (1) 0 6 (8)
Severe 0 0 1 (1)
Decreased appetite 9 (12) 15 (20) 17 (23)
Mild 9 (12) 9 (12) 13 (18)
Moderate 0 6 (8) 3 (4)
Severe 0 0 1 (1)
Alanine aminotransferase level
increasedb
0 9 (12) 16 (22)
Mild 0 7 (9) 6 (8)
Moderate 0 2 (3) 10 (14)
Aspartate aminotransferase level
increasedb
0 8 (11) 14 (19)
Mild 0 7 (9) 6 (8)
Moderate 0 1 (1) 8 (11)
Vomiting 7 (9) 13 (17) 13 (18)
Mild 7 (9) 8 (11) 9 (12)
Moderate 0 4 (5) 4 (6)
Severe 0 1 (1) 0
Pyrexia 6 (8) 14 (19) 12 (16)
Mild 4 (5) 13 (17) 9 (12)
Moderate 2 (3) 1 (1) 3 (4)
Nasopharyngitis 12 (16) 11 (15) 11 (15)
Mild 12 (16) 11 (15) 10 (14)
Moderate 0 0 1 (1)
γ-Glutamyltransferase level increasedb 0 12 (16) 10 (14)
Mild 0 11 (15) 8 (11)
Moderate 0 1 (1) 2 (3)
Seizure 5 (7) 5 (7) 8 (11)
Mild 4 (5) 2 (3) 7 (10)
Moderate 1 (1) 2 (3) 1 (1)
Severe 0 1 (1) 0
Upper respiratory tract infection 10 (13) 7 (9) 7 (10)
Mild 8 (11) 6 (8) 7 (10)
Moderate 2 (3) 1 (1) 0
Constipation 6 (8) 8 (11) 5 (7)
Mild 6 (8) 6 (8) 4 (6)
Moderate 0 2 (3) 1 (1)
Cough 5 (7) 8 (11) 3 (4)
Mild 5 (7) 7 (9) 3 (4)
Moderate 0 1 (1) 0
Abbreviations: CBD25, cannabidiol
25 mg/kg/day; CBD50, cannabidiol
50 mg/kg/day.
a Adverse events occurring in at least
10% of patients in any of the
treatment groups are reported.
b Liver enzyme level elevations
include only those reported as an
adverse event; see eTable 8 in
Supplement 1 for all elevations
regardless of adverse event status.
Severity of an adverse event was
determined by the investigators and
did not involve independent
adjudication.
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inhibitor tacrolimus.27 Therefore, use of cannabidiol as an ad-
junctive treatment in patients taking these medications may
necessitate dosage adjustments; no patient in this study was
taking concomitant mTOR inhibitors.
The cannabidiol dosage range of 25 to 50 mg/kg/day
used in this study was informed by data from a cohort of
patients with TSC (N = 18) in an expanded access program
with the same cannabidiol formulation. In this study, both
dosages showed similar efficacy but differing safety profiles.
The safety profile of the 25 mg/kg/day dosage was consistent
with the highest dosage (20 mg/kg/day) tested in prior trials;
however, dosages greater than 25 mg/kg/day were associ-
ated with higher incidences of certain adverse and serious
adverse events, with half of the patients randomized to
50 mg/kg/day unable to reach or maintain that dosage.
Given the high proportion of patients in the CBD50 group
who were not actually taking 50 mg/kg/day, we performed
multiple sensitivity analyses excluding these patients, and
there was still no difference in efficacy between the CBD25
and the CBD50 groups.
The most frequent adverse event leading to withdrawal
were transient liver enzyme level elevation. The known po-
tential for drug-induced liver injury with cannabidiol, as de-
fined by an alanine aminotransferase level elevation greater
than 5 times the upper limit of the normal range,28 especially
with concomitant valproate, was confirmed in this study.
Transaminase level elevations were more pronounced in pa-
tients taking concomitant valproate and/or 50 mg/kg/day of
cannabidiol and those with baseline alanine aminotransfer-
ase elevations. All patients with drug-induced liver injury re-
covered, and none of the elevations in bilirubin levels met the
Hy’s Law criteria. Overall, cannabidiol had an acceptable safety
profile, with the clinical trial physicians managing adverse
events associated with the accelerated titration scheme in this
study by dosage reduction or treatment discontinuation.
Limitations
This trial is not without limitations. Because most patients in
this trial were taking multiple medications, the potential for
drug-drug interactions and their effect on safety and efficacy
should be explored further. Although seizure type classifica-
tion in this trial was confirmed by the Epilepsy Study Consor-
tium, no video-electroencephalographic confirmation of the
individual seizure subtypes was obtained. Potentially be-
cause of enhanced expectations for cannabidiol treatment, a
higher than expected placebo effect was observed; however,
this did not affect statistical significance of the treatment ef-
fect. Finally, long-term evaluation of cannabidiol in patients
with TSC is needed and will be conducted in the ongoing open-
label extension trial.
Conclusions
In patients with TSC and a high baseline burden of treatment-
resistant, primarily focal seizures, add-on cannabidiol signifi-
cantly reduced seizure frequency compared with placebo. The
safety profile in this study is consistent with prior Lennox-
Gastaut and Dravet syndrome studies, with confirmation of
cannabidiol-associated risks of transaminase level elevations
(especially in the presence of valproate) and somnolence and
sedation (especially in the presence of clobazam).
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